Learn more about our Advocacy work.
Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay…
AdvaMed experts gave a presentation on how FDA regulates AI/ML in medical devices and how Medicare reimbursement policy is impacted by digital health technologies.
AdvaMed held a panel discussion with partners at the International Pharmaceutical & Medical Device Privacy Consortium (IPMPC) on U.S. State Privacy Legislation.
In a new op-ed in RealClear Health, AdvaMed President and CEO Scott Whitaker called on the Biden Administration to ensure the medtech industry is considered as it implements policies to…
Today, diabetes was front and center during a Senate HELP Committee hearing, prompting AdvaMed President and CEO Scott Whitaker to release the following statement on the ways life-saving medical technology…
Today, AdvaMedDx submitted comments in response to the Food and Drug Administration’s Proposed Rule: Medical Devices; Laboratory Developed Tests. AdvaMedDx is a division of AdvaMed representing companies that develop in…
Today, AdvaMed President and CEO Scott Whitaker released the following statement upon House passage of The Prematurity Research Expansion and Education for Mothers who deliver Infants Early (PREEMIE) Reauthorization Act:
In testimony today before a key congressional subcommittee hearing, AdvaMed, the Medtech Association, called for a balance in the proposed regulations of the method used to sterilize 20 billion, or…
Today, AdvaMed, the Medtech Association, called on congressional leaders to work together to prevent a federal government shutdown.
Today, following a legislative hearing on improving seniors’ access to innovative medical devices and technologies, AdvaMed President and CEO Scott Whitaker commended the House Energy and Commerce Committee’s Subcommittee on…